Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

被引：32

作者：

Caviglia, Gian Paolo ^{[1
]}

Armandi, Angelo ^{[1
]}

Rosso, Chiara ^{[1
]}

Gaia, Silvia ^{[2
]}

Aneli, Serena ^{[1
,3
]}

Rolle, Emanuela ^{[2
]}

Abate, Maria Lorena ^{[1
]}

Olivero, Antonella ^{[1
]}

Nicolosi, Aurora ^{[1
]}

Guariglia, Marta ^{[1
]}

Ribaldone, Davide Giuseppe ^{[1
]}

Carucci, Patrizia ^{[2
]}

Saracco, Giorgio Maria ^{[1
,2
]}

Bugianesi, Elisabetta ^{[1
,2
]}

机构：

[1] Univ Turin, Dept Med Sci, I-10126 Turin, Italy

[2] AOU Citta Salute & Sci, Gastroenterol Unit, I-10126 Turin, Italy

[3] Univ Padua, Dept Biol, I-35122 Padua, Italy

来源：

CANCERS | 2021年 / 13卷 / 10期

关键词：

adiponectin; AFP; GPC-3; HCC; IL-6; leptin; NAFLD; PIVKA-II; surveillance; SERUM-LEVELS; ADIPONECTIN; SURVEILLANCE; RISK; ULTRASOUND; FIBROSIS; OBESITY; IMPACT; CANCER; AFP;

D O I：

10.3390/cancers13102305

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Circulating biomarkers for the detection of hepatocellular carcinoma in patients with dysmetabolic liver disease are an unmet need. In the present study, we observed that serum values of five biomarkers (namely, AFP, PIVKA-II, GPC-3, adiponectin and IL-6) were significantly different between patients with and without hepatocellular carcinoma; the best accuracy for the detection of tumor was achieved by PIVKA-II. Furthermore, we developed a model combining age, gender, PIVKA-II, GPC-3 and adiponectin that showed an excellent performance for the identification of patients with hepatocellular carcinoma. This model may be useful for the surveillance of patients with dysmetabolic liver disease at risk of hepatocellular carcinoma development. Current surveillance strategy for patients with nonalcoholic fatty liver disease (NAFLD) at risk of hepatocellular carcinoma (HCC) development is unsatisfactory. We aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), glypican-3 (GPC-3), adiponectin, leptin and interleukin-6 (IL-6), alone or in combination, for the discrimination between NAFLD patients with or without HCC. The biomarkers were investigated in a cohort of 191 NAFLD patients (median age 62, 54-68 years; 121 males and 70 females) with advanced fibrosis/cirrhosis, 72 of whom had a diagnosis of HCC. PIVKA-II showed the best performance for the detection of HCC with an area under the curve (AUC) of 0.853, followed by adiponectin (AUC = 0.770), AFP (AUC = 0.763), GPC-3 (AUC = 0.759) and by IL-6 (AUC = 0.731), while the leptin values were not different between patients with and without HCC. The accuracy of the biomarkers' combination was assessed by a stratified cross-validation approach. The combination of age, gender, PIVKA-II, GPC-3 and adiponectin further improved the diagnostic accuracy (AUC = 0.948); the model correctly identified the 87% of the patients. In conclusion, we developed a model with excellent accuracy for the detection of HCC that may be useful to improve the surveillance of NAFLD patients at risk of tumor development.

引用

页数：12

共 56 条

[31] Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases [J].